Top Ten most read pages on Pharmafile.com this week
pharmafile | June 9, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | biggest news, biggest stories, top 10, top 10 stories, top stories, top ten
It’s been a week for successful trial news and for drugs being sped through the approval process. Particularly noteworthy is our most read story, featuring CAR T trials showing serious promise. Read here to follow our top ten most read articles and catch up on the major news of the week:
10. AbbVie posts promising data on RA drug
AbbVie posted results on upadacitinib, the latest drug in its pipeline for rheumatoid arthritis (RA), and the results have given the company a huge boost by managing to hit all endpoints of the trial.
9. Pfizer gets fast-track approval for rare heart condition
Pfizer’s tafamidis has already been given approval in 40 countries across the globe but it has not currently broken into the US market. This could soon to be set to change as it has received a fast-track designation for the treatment of transthyretin cardiomyopathy (TTR-CM).
8. BMS’ Opdivo scores eighth approval in Europe for bladder cancer
Bristol-Myers Squibb announced that Opdivo (nivolumab) has secured its eighth approval in Europe for the treatment of locally-advanced unresectable or metastatic urothelial carcinoma (mUC) in adults following the failure of prior platinum-containing therapy.
7. Takeda launches construction of €40 million Dublin facility
Takeda officially launched the construction of a new €40 million production facility in Dublin, Ireland, with a ground-breaking ceremony.
6. Merck KGaA signs potential $1 billion deal with UK biotech
UK biotech, F-Star, scored a boost to its coffers with another link-up with a big pharma company, this time with Merck KGaA. The deal sees €115 million exchange hands in the initial stages of the agreement.
5. AbbVie names new General Managers for UK and France
Abbvie announced a double appointment across its UK and French operations, naming Jérôme Bouyer as its UK General Manager, UK, and Pierre-Claude Fumoleau succeeds him as General Manager, France
4. Novartis and IBM form breast cancer research partnership
News broke that Novartis is to join forces with tech giant IBM, and its Watson Health platform, to tackle advanced breast cancer with an outcome-based initiative.
3. 1 in 6 US patients are given wrong dose of blood-thinners, study suggests
New research data from the Mayo Clinic has suggested that as much as one in six patients suffering from atrial fibrillation have been prescribed the wrong dose of blood-thinning medication as a treatment.
2. New game, new rules: Pathways for better and more affordable medicines in Europe
Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines at the European Public Health Alliance (EPHA), discusses the latest developments in market access across Europe, and the collaborative efforts its constituents are engaging in to improve it.
1. Unprecedented CAR-T data shows 100% response rate
In a study examining patients suffering from multiple myeloma, CAR-T therapy achieved a 100% response rate across all participants, with every one but two reaching some form of remission within two months.
Related Content
Pharmafile.com’s top 10 news stories of the week
Among our ten most-read stories this week: NICE has announced that more patients are eligible …
Pharmafile.com’s top 10 news stories of the week
In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer …
Top Ten most popular articles on Pharmafile.com this week
With just around three weeks until the end of a long year, rapidly emerging news …
